JASN:尿可溶性CD163预测活动性肾血管炎

2016-09-27 xing.T MedSci原创

这些数据表明,尿中可溶性CD163水平与活动性肾血管炎密切相关,测量尿中可溶性CD163水平可作为诊断活动性肾血管炎的一种无创性手段,具有重要的临床诊断价值。

由于缺乏一个特定的生物标志物鉴别活动性肾血管炎和其他肾功能不全疾病,因此往往需要依赖于肾活检。可溶性CD163可由单核细胞和巨噬细胞合成及分泌,它被报道可作为与巨噬细胞过度活化相关疾病的一种潜在生物标志物。


因此,来自爱尔兰都柏林大学三一学院免疫学教研室的Vincent P.O’Reilly学者及其团队推测由新月巨噬细胞产生的尿中可溶性CD163与活动性肾小球炎症相关,相关研究成果发表于肾脏病领域权威杂志《Journal of the American Society of Nephrology》上。

首先,研究者在实验性血管炎发病早期的大鼠尿液中检测到了可溶性CD163。此外,相比于狼疮性肾炎患者、糖尿病肾病或肾病综合征患者,从小血管炎患者显微分离出的肾小球中检测到了显著升高的CD163mRNA分子。无论是肾小球还是肾间质,血管炎患者高表达CD163蛋白分子。

在479个研究对象中,包括有小血管炎组、疾病对照组和健康对照组,三组之间血清可溶性CD163水平没有差异。然而,在有177例研究对象的小血管炎组,活动性肾血管炎患者尿中可溶性CD163水平比缓解期患者、其他疾病对照组和健康对照组要明显升高。将用于检测活动性肾血管炎的最佳尿中可溶性CD163分子诊断值设置为0.3ng/mmol肌酐,其敏感性为83%,特异性为96%,阳性似然比为20.8。

这些数据表明,尿中可溶性CD163水平与活动性肾血管炎密切相关,测量尿中可溶性CD163水平可作为诊断活动性肾血管炎的一种无创性手段,具有重要的临床诊断价值。

原始出处:

Vincent P.O’Reilly, et al.Urinary Soluble CD163 in Active Renal Vasculitis. Journal of the American Society of Nephrology.2016;9:e004950.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1782706, encodeId=25ba1e8270699, content=<a href='/topic/show?id=fd1042e4ea' target=_blank style='color:#2F92EE;'>#CD16#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4274, encryptionId=fd1042e4ea, topicName=CD16)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Sun Sep 03 06:03:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723901, encodeId=80b21e2390103, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Sun Dec 25 13:03:00 CST 2016, time=2016-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941287, encodeId=6918194128e88, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Sun Jan 22 03:03:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263159, encodeId=1ebc126315950, content=<a href='/topic/show?id=581e8968859' target=_blank style='color:#2F92EE;'>#血管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89688, encryptionId=581e8968859, topicName=血管炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Thu Sep 29 08:03:00 CST 2016, time=2016-09-29, status=1, ipAttribution=)]
    2017-09-03 yeye5224612
  2. [GetPortalCommentsPageByObjectIdResponse(id=1782706, encodeId=25ba1e8270699, content=<a href='/topic/show?id=fd1042e4ea' target=_blank style='color:#2F92EE;'>#CD16#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4274, encryptionId=fd1042e4ea, topicName=CD16)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Sun Sep 03 06:03:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723901, encodeId=80b21e2390103, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Sun Dec 25 13:03:00 CST 2016, time=2016-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941287, encodeId=6918194128e88, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Sun Jan 22 03:03:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263159, encodeId=1ebc126315950, content=<a href='/topic/show?id=581e8968859' target=_blank style='color:#2F92EE;'>#血管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89688, encryptionId=581e8968859, topicName=血管炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Thu Sep 29 08:03:00 CST 2016, time=2016-09-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1782706, encodeId=25ba1e8270699, content=<a href='/topic/show?id=fd1042e4ea' target=_blank style='color:#2F92EE;'>#CD16#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4274, encryptionId=fd1042e4ea, topicName=CD16)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Sun Sep 03 06:03:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723901, encodeId=80b21e2390103, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Sun Dec 25 13:03:00 CST 2016, time=2016-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941287, encodeId=6918194128e88, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Sun Jan 22 03:03:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263159, encodeId=1ebc126315950, content=<a href='/topic/show?id=581e8968859' target=_blank style='color:#2F92EE;'>#血管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89688, encryptionId=581e8968859, topicName=血管炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Thu Sep 29 08:03:00 CST 2016, time=2016-09-29, status=1, ipAttribution=)]
    2017-01-22 chenhongpeng
  4. [GetPortalCommentsPageByObjectIdResponse(id=1782706, encodeId=25ba1e8270699, content=<a href='/topic/show?id=fd1042e4ea' target=_blank style='color:#2F92EE;'>#CD16#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4274, encryptionId=fd1042e4ea, topicName=CD16)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Sun Sep 03 06:03:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723901, encodeId=80b21e2390103, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Sun Dec 25 13:03:00 CST 2016, time=2016-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941287, encodeId=6918194128e88, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Sun Jan 22 03:03:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263159, encodeId=1ebc126315950, content=<a href='/topic/show?id=581e8968859' target=_blank style='color:#2F92EE;'>#血管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89688, encryptionId=581e8968859, topicName=血管炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Thu Sep 29 08:03:00 CST 2016, time=2016-09-29, status=1, ipAttribution=)]